DelveInsight’s, “Dermatomyositis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dermatomyositis pipeline landscape. It covers the Dermatomyositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dermatomyositis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Dermatomyositis Pipeline? Click here to explore the therapies and trials making headlines @ Dermatomyositis Pipeline Outlook Report
Key Takeaways from the Dermatomyositis Pipeline Report
- On 15 September 2025, Cabaletta Bio announced a study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
- On 11 September 2025, AstraZeneca conducted a study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) [polymyositis (PM) or dermatomyositis (DM)] while receiving standard of care (SoC) treatment.
- DelveInsight’s Dermatomyositis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Dermatomyositis treatment.
- The leading Dermatomyositis Companies such as Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
- Promising Dermatomyositis Therapies such as Brepocitinib, Lenabasum 20 mg, GLPG3667, Octagam 10%, Tocilizumab, PN-101, KZR-616 and others.
Want to know which companies are leading innovation in Dermatomyositis? Dive into the full pipeline insights @ Dermatomyositis Clinical Trials Assessment
The Dermatomyositis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Dermatomyositis Pipeline Report also highlights the unmet needs with respect to the Dermatomyositis.
Dermatomyositis Overview
Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by muscle weakness and distinctive skin manifestations. This idiopathic inflammatory myopathy primarily affects the proximal muscles, including the hips, thighs, shoulders, and neck, leading to progressive and symmetrical weakness that can significantly impair daily activities. Skin symptoms include Gottron’s papules, which are raised, scaly bumps on the knuckles, elbows, and knees, and a heliotrope rash, characterized by a purplish discoloration and swelling around the eyes. Other notable rashes include the V-sign and shawl sign, which appear over the chest and shoulders respectively, as well as mechanic’s hands, which feature rough, cracked skin on the sides of the fingers.
Dermatomyositis Emerging Drugs Profile
- EFG PH20: argenx
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. A Phase II/III study (NCT05523167) is evaluating the efficacy and safety of efgartigimod PH20 SC compared to placebo in adults with active IIMs, including DM, immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), and antisynthetase syndrome. The primary endpoint is treatment response measured by Total Improvement Score (TIS). Another study (NCT05979441) is assessing the long-term safety and efficacy of subcutaneous efgartigimod in adults with IIMs. The drug is currently in Phase III stage of development to treat Dermatomyositis.
- KZR-616: Kezar Life Sciences
KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body’s immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.
If you’re tracking ongoing Dermatomyositis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Dermatomyositis Treatment Drugs
Dermatomyositis Companies
Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
Dermatomyositis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Dermatomyositis Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
From emerging drug candidates to competitive intelligence, the Dermatomyositis Pipeline Report covers it all – check it out now @ Dermatomyositis Market Drivers and Barriers, and Future Perspectives
Scope of the Dermatomyositis Pipeline Report
- Coverage- Global
- Dermatomyositis Companies- Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals and others.
- Dermatomyositis Therapies- Brepocitinib, Lenabasum 20 mg, GLPG3667, Octagam 10%, Tocilizumab, PN-101, KZR-616 and others.
- Dermatomyositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Dermatomyositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Dermatomyositis Treatment landscape in this detailed analysis @ Dermatomyositis Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Dermatomyositis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Dermatomyositis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- EFG PH20: argenx
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- KZR-616: Kezar Life Sciences
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Dermatomyositis Key Companies
- Dermatomyositis Key Products
- Dermatomyositis- Unmet Needs
- Dermatomyositis- Market Drivers and Barriers
- Dermatomyositis- Future Perspectives and Conclusion
- Dermatomyositis Analyst Views
- Dermatomyositis Key Companies
- 24. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight